Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas

British Journal of Cancer

Volumn 110, Issue 7, 2014, Pages 1712-1720

  Schmidt, T ^a   Sicic, L ^a   Blank, S ^a   Becker, K ^b   Weichert, W ^a   Bruckner, T ^a   Parakonthun, T ^a   Langer, R ^c   Buchler M W ^a   Siewert, J R ^d   Lordick, F ^e   Ott, K ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

histopathological regression; localisation; multivariate analysis; neoadjuvant treated; oesophagogastric adenocarcinomas; prognostic factors; signet ring cell cancer; surgery

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; OXALIPLATIN; PACLITAXEL;

ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER LOCALIZATION; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CLINICAL EVALUATION; ESOPHAGOGASTRIC ADENOCARCINOMA; ESOPHAGUS DISEASE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PATIENT CODING; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SIGNET RING CARCINOMA; STOMACH CANCER; STOMACH DISEASE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; DIAGNOSTIC VALUE; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; GASTRECTOMY; HUMAN TISSUE; MEDICAL RECORD REVIEW; MULTICENTER STUDY; PREOPERATIVE TREATMENT; STOMACH ADENOCARCINOMA; VERY ELDERLY;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TUMOR BURDEN; YOUNG ADULT;

EID: 84897573913     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.94     Document Type: Article

References (44)

1. Bader FG, Lordick F, Fink U, Becker K, Hofler H, Busch R, Siewert JR, Ott K (2008) Paclitaxel in the neoadjuvant treatment for adeno carcinoma of the distal esophagus (AEG I). A comparison of two phase II trials with long-term follow-up. Onkologie 31: 366-372.
2. Becker K, Langer R, Reim D, Novotny A, Meyer zum Buschenfelde C, Engel J, Friess H, Hofler H (2011) Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg 253: 934-939.
3. Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, Bottcher K, Siewert JR, Hofler H (2003) Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98: 1521-1530.
4. Blank S, Blaker H, Schaible A, Lordick F, Grenacher L, Buechler M, Ott K (2012) Impact of pretherapeutic routine clinical staging for the individualization of treatment in gastric cancer patients. Langenbecks Arch Surg 397: 45-55.
5. Blank S, Stange A, Sisic L, Roth W, Grenacher L, Sterzing F, Burian M, Jager D, Buchler M, Ott K (2013) Preoperative therapy of esophagogastric cancer: the problem of nonresponding patients. Langenbecks Arch Surg 398: 211-220.
6. Bollschweiler E, Holscher AH, Metzger R, Besch S, Monig SP, Baldus SE, Drebber U (2011) Prognostic significance of a new grading system of lymph node morphology after neoadjuvant radiochemotherapy for esophageal cancer. Ann Thorac Surg 92: 2020-2027.
7. Burmeister BH, Thomas JM, Burmeister EA, Walpole ET, Harvey JA, Thomson DB, Barbour AP, Gotley DC, Smithers BM (2011) Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer 47: 354-360.
8. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, Participants MT (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355: 11-20.
9. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358: 36-46.
10. Fields RC, Strong VE, Gonen M, Goodman KA, Rizk NP, Kelsen DP, Ilson DH, Tang LH, Brennan MF, Coit DG, Shah MA (2011) Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma. Br J Cancer 104: 1840-1847.
11. Fujitani K, Mano M, Hirao M, Kodama Y, Tsujinaka T (2012) Posttherapy nodal status, not graded histologic response, predicts survival after neoadjuvant chemotherapy for advanced gastric cancer. Ann Surg Oncol 19: 1936-1943.
12. Gertler R, Stein HJ, Langer R, Nettelmann M, Schuster T, Hoefler H, Siewert JR, Feith M (2011) Long-term outcome of 2920 patients with cancers of the esophagus and esophagogastric junction: evaluation of the New Union Internationale Contre le Cancer/American Joint Cancer Committee staging system. Ann Surg 253: 689-698.
13. Heidecke CD, Weighardt H, Feith M, Fink U, Zimmermann F, Stein HJ, Siewert JR, Holzmann B (2002) Neoadjuvant treatment of esophageal cancer: Immunosuppression following combined radiochemotherapy. Surgery 132: 495-501.
14. Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, Stalmeier PF, ten Kate FJ, van Dekken H, Obertop H, Tilanus HW, van Lanschot JJ (2002) Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. New Engl J Med 347: 1662-1669.
15. Koh YW, Park YS, Ryu MH, Ryoo BY, Park HJ, Yook JH, Kim BS, Kang YK (2013) Postoperative nodal status and diffuse-type histology are independent prognostic factors in resectable advanced gastric carcinomas after preoperative chemotherapy. Am J Surg Pathol 37: 1022-1029.
16. Kunz PL, Gubens M, Fisher GA, Ford JM, Lichtensztajn DY, Clarke CA (2012) Long-term survivors of gastric cancer: a California populationbased study. J Clin Oncol 30: 3507-3515.
17. Kurihara M, Aiko T (2001) The new Japanese classification of gastric carcinoma: revised explanation of 'response assessment of chemotherapy and radiotherapy for gastric carcinoma'. Gastric Cancer 4: 9-13.
18. Langer R, Ott K, Feith M, Lordick F, Siewert JR, Becker K (2009) Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas. Mod Pathol 22: 1555-1563.
19. Lim JTW, Truong PT, Berthelet E, Pai H, Joe H, Wai E, Larsson S, Kader HA, Weinerman B, Wilson K, Olivotto IA (2003) Endoscopic response predicts for survival and organ preservation after primary chemoradiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 57: 1328-1335.
20. Lorenzen S, Blank S, Lordick F, Siewert JR, Ott K (2012) Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients. Ann Surg Oncol 19: 2119-2127.
21. Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA (1999) Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 229: 303-308.
22. Lutz MP, Zalcberg JR, Ducreux M, Ajani JA, Allum W, Aust D, Bang YJ, Cascinu S, Holscher A, Jankowski J, Jansen EP, Kisslich R, Lordick F, Mariette C, Moehler M, Oyama T, Roth A, Rueschoff J, Ruhstaller T, Seruca R, Stahl M, Sterzing F, van Cutsem E, van der Gaast A van Lanschot J, Ychou M, Otto F (2012) Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer-differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer 48: 2941-2953.
23. Mansour JC, Tang L, Shah M, Bentrem D, Klimstra DS, Gonen M, Kelsen DP, Brennan MF, Coit DG (2007) Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer? Ann Surg Oncol 14: 3412-3418.
24. Messager M, Lefevre JH, Pichot-Delahaye V, Souadka A, Piessen G, Mariette C (2011) The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study. Ann Surg 254: 684-693discussion 693.
25. Ott K, Bader FG, Lordick F, Feith M, Bartels H, Siewert JR (2009) Surgical factors influence the outcome after Ivor-Lewis esophagectomy with intrathoracic anastomosis for adenocarcinoma of the esophagogastric junction: a consecutive series of 240 patients at an experienced center. Ann Surg Oncol 16: 1017-1025.
26. Ott K, Blank S, Becker K, Langer R, Weichert W, Roth W, Sisic L, Stange A, Jager D, Buchler M, Siewert JR, Lordick F (2013) Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10% residual tumor. Langenbecks Arch Surg 398: 239-249.
27. Ott K, Lordick F, Herrmann K, Krause BJ, Schuhmacher C, Siewert JR (2008) The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies. Gastric Cancer 11: 1-9.
28. Ott K, Sendler A, Becker K, Dittler HJ, Helmberger H, Busch R, Kollmannsberger C, Siewert JR, Fink U (2003) Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer 6: 159-167.
29. Reim D, Gertler R, Novotny A, Becker K, zum Buschenfelde CM, Ebert M, Dobritz M, Langer R, Hoefler H, Friess H, Schumacher C (2012) Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer. Ann Surg Oncol 19: 2108-2118.
30. Reim D, Loos M, Vogl F, Novotny A, Schuster T, Langer R, Becker K, Hofler H, Siveke J, Bassermann F, Friess H, Schuhmacher C (2013) Prognostic implications of the seventh edition of the international union against cancer classification for patients with gastric cancer: the Western experience of patients treated in a single-center European institution. J Clin Oncol 31: 263-271.
31. Schneider PM, Metzger R, Schaefer H, Baumgarten F, Vallbohmer D, Brabender J, Wolfgarten E, Bollschweiler E, Baldus SE, Dienes HP, Hoelscher AH (2008) Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer. Ann Surg 248: 902-908.
32. Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J, Ott K, Hoelscher A, Schneider PM, Bechstein W, Wilke H, Lutz MP, Nordlinger B, Van Cutsem E, Siewert JR, Schlag PM (2010) Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 28: 5210-5218.
33. Siewert JR, Ott K (2007) Are squamous and adenocarcinomas of the esophagus the same disease? Semin Radiat Oncol 17: 38-44.
34. Siewert JR, Stein HJ, Feith M, Bruecher BL, Bartels H, Fink U (2001) Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg 234: 360-367; discussion 368-9.
35. Sisic L, Blank S, Weichert W, Jager D, Springfeld C, Hochreiter M, Buchler M, Ott K (2013) Prognostic impact of lymph node involvement and the extent of lymphadenectomy (LAD) in adenocarcinoma of the esophagogastric junction (AEG). Langenbecks Arch Surg.
36. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V (2011) Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 12: 681-692.
37. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, Langer P, Engenhart-Cabillic R, Bitzer M, Konigsrainer A, Budach W, Wilke H (2009) Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 27: 851-856.
38. Taghavi S, Jayarajan SN, Davey A, Willis AI (2012) Prognostic significance of signet ring gastric cancer. J Clin Oncol 30: 3493-3498.
39. UICC (2010) TNM Classification of Malignant Tumours. 7th edn. WCW-L: New York, NY.
40. Vallbohmer D, Holscher AH, DeMeester S, DeMeester T, Salo J, Peters J, Lerut T, Swisher SG, Schroder W, Bollschweiler E, Hofstetter W (2010) A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer. Ann Surg 252: 744-749.
41. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366: 2074-2084.
42. von Rahden BH, Stein HJ, Feith M, Becker K, Siewert JR (2005) Lymphatic vessel invasion as a prognostic factor in patients with primary resected adenocarcinomas of the esophagogastric junction. J Clin Oncol 23: 874-879.
43. Weber WA, Petersen V, Schmidt B, Tyndale-Hines L, Link T, Peschel C, Schwaiger M (2003) Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 21: 2651-2657.
44. Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Geneve J, Lasser P, Rougier P (2011) Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29: 1715-1721.